|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Medicine/SFVAMC, University of California, San Francisco, San Francisco, California, United States
2 Medicine/SFVAMC, University of California, San Francisco, San Francisco, California, United States; Medicine, UCSF, United States
3 Medicine/SFVAMC, University of California, San Francisco, San Francisco, California, United States; V. A. Medical Center, Cardiology Dept. - 111-C8, San Francisco, California, United States
4 Nephrology Section (111J), V.A. Medical Center, San Francisco, California, United States
* To whom correspondence should be addressed. E-mail: david.lovett{at}med.va.gov.
Although enhanced cardiac matrix metalloproteinase-2 (MMP-2) synthesis has been associated with ventricular remodeling and failure, whether MMP-2 expression is a direct mediator of this process is unknown. We generated transgenic mice expressing active MMP-2 driven by the
-myosin heavy chain promoter. At 4 months MMP-2 transgenic hearts demonstrated expression of the MMP-2 transgene, myocyte hypertrophy, breakdown of Z-band registration, lysis of myofilaments, disruption of sarcomere and mitochondrial architecture, and cardiac fibroblast proliferation. Hearts from 8 month old transgenic mice displayed extensive myocyte disorganization and dropout with replacement fibrosis and perivascular fibrosis. Older transgenic mice also exhibited a massive increase in cardiac MMP-2 expression, representing recruitment of endogenous MMP-2 synthesis, with associated expression of MMP-9 and MT1-MMP. Increases in diastolic (C, 33 ± 3 vs. MMP, 51 ± 12 µl; p=0.003) and systolic (C, 7 ± 2 vs. MMP, 28 ± 14 µl; p=0.003) LV volumes and relatively preserved stroke volume (C, 26 ± 4 vs. MMP, 23 ± 3 µl; p=0.16) resulted in markedly decreased LV ejection fraction (C, 78 ± 7 vs. MMP, 48 ± 16%; p=0.0006). Markedly impaired systolic function in the MMP transgenic mice was demonstrated in the reduced preload adjusted maximal power (C, 240 ± 84 vs. MMP, 78 ± 49 mWatts/µl2; p=0.0003) and decreased end-systolic pressure volume relation (Eea; C, 7.5 ± 1.5 vs. MMP, 4.7 ± 2.0; p=0.016). Expression of active MMP-2 is sufficient to induce severe ventricular remodeling and systolic dysfunction in the absence of superimposed injury.
This article has been cited by other articles:
![]() |
A. D. Kandasamy and R. Schulz Glycogen synthase kinase-3{beta} is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts Cardiovasc Res, September 1, 2009; 83(4): 698 - 706. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, T. Oka, F. L. Chow, S. B. Cooper, J. Odenbach, G. D. Lopaschuk, Z. Kassiri, and C. Fernandez-Patron Tumor Necrosis Factor-{alpha}-Converting Enzyme Is a Key Regulator of Agonist-Induced Cardiac Hypertrophy and Fibrosis Hypertension, September 1, 2009; 54(3): 575 - 582. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Kandasamy, A. K. Chow, M. A.M. Ali, and R. Schulz Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix Cardiovasc Res, August 20, 2009; (2009) cvp268v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Spinale, G. P. Escobar, R. Mukherjee, J. A. Zavadzkas, S. M. Saunders, L. B. Jeffords, A. M. Leone, C. Beck, S. Bouges, and R. E. Stroud Cardiac-Restricted Overexpression of Membrane Type-1 Matrix Metalloproteinase in Mice: Effects on Myocardial Remodeling With Aging Circ Heart Fail, July 1, 2009; 2(4): 351 - 360. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Biolo, S. Ramamurthy, L. H. Connors, C. J. O'Hara, H. K. Meier-Ewert, P. T. Soo Hoo, D. B. Sawyer, D. S. Seldin, and F. Sam Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis: Relationship to Structural, Functional Myocardial Changes and to Light Chain Amyloid Deposition Circ Heart Fail, November 1, 2008; 1(4): 249 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. T. McCloskey, S. Turcato, G.-Y. Wang, L. Turnbull, B.-Q. Zhu, T. Bambino, A. P. Nguyen, D. H. Lovett, R. A. Nissenson, J. S. Karliner, et al. Expression of a Gi-coupled receptor in the heart causes impaired Ca2+ handling, myofilament injury, and dilated cardiomyopathy Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H205 - H212. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |